Comparative analysis of BCG vaccination routes in mice reveals preferential reprogramming of pulmonary macrophages upon mucosal administration

This study demonstrates that mucosal intratracheal BCG vaccination in mice uniquely reprograms interstitial macrophages and establishes spatially organized immune hubs with CD4 T cells, resulting in superior protection against tuberculosis compared to intravenous or subcutaneous routes.

The Gist

The Big Picture: A New Way to Train the Body's "Security Guards"

Imagine your lungs are a massive, bustling city. Inside this city, there are two main types of security guards (immune cells) patrolling the streets:

1. Alveolar Macrophages (AM): These are the guards standing right at the front gates (the airways), ready to grab anyone trying to enter.
2. Interstitial Macrophages (IM): These are the neighborhood patrol officers living deep inside the city blocks (the lung tissue). They are the ones who actually stop infections from spreading once they get past the front gate.

For decades, the only vaccine we have against Tuberculosis (TB) is called BCG. It's like a basic training course for these guards. However, the standard way of giving this vaccine (a shot under the skin) is like sending a training manual via mail—it gets the guards' attention, but they don't get very good at their jobs.

The Big Discovery: This study found that if you deliver the vaccine directly into the lungs (like spraying it in), it doesn't just wake up the front-door guards; it completely reprograms the neighborhood patrol officers (the Interstitial Macrophages) to become elite, super-efficient fighters.

---

The Experiment: Three Different Training Methods

The researchers took mice and gave them the BCG vaccine in three different ways to see which method trained the "city guards" best:

1. Subcutaneous (SC): A shot under the skin (the old, standard way).
2. Intravenous (IV): Injected directly into the bloodstream (a method known to work well in primates).
3. Intratracheal (IT): Sprayed directly into the windpipe/lungs (the "mucosal" method).

The Result:

• The Skin Shot (SC): The guards barely noticed. They stayed mostly the same as untrained guards.
• The Blood Shot (IV): The guards got a good workout. They became more active and alert.
• The Lung Spray (IT): This was the magic bullet. It didn't just wake the guards up; it rewired their brains.

The "Super-Training" Effect

When the vaccine was sprayed into the lungs, the Interstitial Macrophages (the deep-tissue patrol) underwent a massive transformation. Think of it like upgrading a regular police officer into a SWAT team member overnight.

• Metabolic Overdrive: These cells started burning energy faster (like switching from a hybrid car to a rocket engine) to be ready for battle.
• Weaponry: They started producing more "anti-bacterial weapons" (proteins like NOS2) that can kill TB bacteria instantly.
• The T-Cell Alliance: The most exciting part? These super-trained macrophages started building specialized training hubs (called iBALT) deep in the lung tissue. In these hubs, they formed a perfect team with CD4 T-cells (the commanders).
  • The Analogy: The macrophages act like a lighthouse, sending out chemical signals (like a radio beacon) that call the T-cell commanders right to their side. Once they are together, they shout instructions to each other, creating a defensive wall that the bacteria cannot break through.

Why This Matters: The "Cross-Protection" Test

To prove these new "super guards" were actually useful, the researchers challenged the mice with two different enemies:

1. TB (The original enemy): The mice vaccinated with the lung spray were the best at stopping the TB bacteria. They had the lowest infection rates.
2. Pseudomonas (A totally different germ): Even though the vaccine was designed for TB, the lung-sprayed mice were also much better at fighting off this different bacteria.

The Takeaway: The lung spray didn't just teach the guards how to fight TB; it gave them a general "super-soldier" mindset that made them better at fighting any invader.

The "Why" Behind the Magic

The researchers discovered that the route of delivery is everything.

• When you shoot the vaccine under the skin, the immune system treats it like a distant threat.
• When you spray it into the lungs, the immune system realizes, "Oh no, the enemy is already inside the city!" This triggers an immediate, intense, and highly organized response that reprograms the deep-tissue guards to stay on high alert permanently.

The Bottom Line

This study suggests that how we give a vaccine is just as important as what is in the vaccine. By changing the delivery method from a skin shot to a lung spray, we can turn our body's natural defenses into a highly coordinated, super-powered defense network.

This opens the door for new, better vaccines not just for Tuberculosis, but for other respiratory diseases like the flu or pneumonia, by teaching our lungs to be their own best defenders.

Technical Summary

1. Problem Statement

• Context: Tuberculosis (TB) remains a leading cause of infectious death. The Bacille Calmette-Guérin (BCG) vaccine is the only licensed TB vaccine but offers inconsistent protection against pulmonary disease.
• Knowledge Gap: While recent studies in non-human primates (NHPs) show that intravenous (IV) BCG provides superior protection compared to intradermal (ID) vaccination, the mechanistic basis of how different vaccination routes reprogram lung immunity in mice (the primary model for mechanistic studies) is not fully defined at single-cell or spatial resolution.
• Specific Focus: Most research focuses on Alveolar Macrophages (AM), which reside in airspaces. The role of Interstitial Macrophages (IM), which occupy the lung parenchyma and are known to be restrictive to Mycobacterium tuberculosis (Mtb) growth, in response to vaccination remains largely unexplored. It is unclear if alternative vaccination routes (mucosal vs. systemic) can reprogram IM to enhance antimicrobial defense.

2. Methodology

The study employed a multi-omics approach to compare three BCG vaccination routes in C57BL/6 mice: Subcutaneous (SC), Intravenous (IV), and Intratracheal (IT).

• Vaccination & Challenge: Mice were vaccinated with BCG Pasteur. Protection was assessed via:
  • Mtb Challenge: Aerosolized M. tuberculosis (HN878 strain) challenge 8 weeks post-vaccination, with bacterial burden measured at 14 days.
  • Heterologous Challenge: Acute infection with Pseudomonas aeruginosa (PA) to assess innate immune licensing independent of antigen-specific memory.
• Flow Cytometry: High-dimensional analysis of lung immune cells at 4, 8, and 12 weeks post-vaccination. Markers included activation (CD80, CD86, MHCII), residency (CD69, CD45-), and antimicrobial effectors (NOS2, CD38).
• Single-Cell RNA Sequencing (scRNA-seq): Performed on CD45+ lung cells 8 weeks post-vaccination.
  • Used CITE-seq (Cellular Indexing of Transcriptomes and Epitopes) to integrate surface protein data with transcriptomics.
  • Analyzed myeloid (AM, IM, DCs) and lymphoid (CD4/CD8 T cells) populations.
  • Tools: STARsolo, Seurat, UCell (signature scoring), NicheNet (cell-cell communication).
• Spatial Transcriptomics: Used 10x Genomics Visium to map the spatial distribution of immune cells and gene expression signatures in lung tissue sections.
• Antibiotic Treatment: Mice were treated with antibiotics (rifampicin/isoniazid) post-vaccination to determine if the observed phenotypes required the continued presence of viable BCG.

3. Key Contributions & Results

A. Route-Specific Reprogramming of Macrophages

• Alveolar Macrophages (AM): Both IT and IV vaccination increased activation markers (CD80, CD86, MHCII) and the frequency of CD38+ and NOS2+ AM compared to SC.
• Interstitial Macrophages (IM):
  • IT Vaccination Uniquely Expanded IM: IT delivery caused a significant increase in the absolute number and frequency of IM, which was not observed with SC or IV routes.
  • Transcriptional Rewiring: scRNA-seq revealed that IT BCG induced the most profound transcriptional changes in IM. A distinct Cluster 1 of IM emerged exclusively after IT (and IV) vaccination.
  • Gene Signatures: IT-induced IM upregulated genes associated with:
    • Interferon Response: Cxcl9, Gbp2, Stat1, Cd274.
    • Metabolism: Glycolysis (Gapdh, Pkm) and Oxidative Phosphorylation (Oxphos).
    • Antimicrobial Effectors: High expression of NOS2.
  • Persistence: Antibiotic treatment did not abolish the IM phenotype, suggesting epigenetic "training" rather than dependence on live bacteria.

B. CD4 T Cell Dynamics and Crosstalk

• T Cell Activation: IT vaccination increased the number of lung-resident CD4+ T cells (CD45- CD69+).
• Distinct Clusters:
  • Cluster 3: Resembled CX3CR1hi effector memory T cells (induced by IV BCG in prior literature).
  • IT-Specific Features: IT-induced CD4 T cells showed enhanced metabolic activity and expression of homing receptors (CXCR3, CXCR6).
• Bidirectional Signaling (NicheNet Analysis):
  • CD4 $\to$ IM: CD4 T cells are the primary source of IFN$\gamma$, signaling through Ifngr1/2 on IM to drive activation.
  • IM $\to$ CD4: IT-vaccinated IM upregulated chemokines Ccl3, Cxcl10, and Cxcl16.
  • The CXCL16/CXCR6 Axis: IM-derived CXCL16 signals to CXCR6 on CD4 T cells, creating a positive feedback loop that recruits and retains T cells in the lung. This circuit was most robust in IT-vaccinated mice.

C. Spatial Organization (iBALT)

• Spatial Transcriptomics: Revealed that IT and IV vaccination induced the formation of distinct tissue niches (Clusters 18 and 19) enriched with activated IM, B cells, and CD4 T cells.
• iBALT Formation: These regions resemble inducible Bronchus-Associated Lymphoid Tissue (iBALT). The co-localization of activated IM and CD4 T cells in these niches suggests a structural basis for sustained immune crosstalk.
• SC Vaccination: Did not induce these specific spatial clusters or iBALT-like structures.

D. Functional Protection

• Mtb Challenge: IT-vaccinated mice showed the lowest bacterial burden (superior protection) compared to IV and SC groups.
• NOS2 Expression: Upon Mtb challenge, IM from IT-vaccinated mice maintained high NOS2 expression, correlating with bacterial control.
• Heterologous Protection (P. aeruginosa): IT (and IV) vaccination significantly reduced P. aeruginosa load compared to SC.
  • Mechanism: IM from IT-vaccinated mice showed a unique phenotype upon PA challenge: high NOS2 (bacterial killing) and low Arg1 (pro-inflammatory resolution), with a subset co-expressing both markers. This indicates IT vaccination "licenses" IM for rapid, potent antimicrobial responses independent of specific antigen recognition.

4. Significance

• Redefining Macrophage Roles: The study shifts the focus from Alveolar Macrophages to Interstitial Macrophages as the critical mediators of mucosal vaccine-induced protection.
• Mechanism of Mucosal Immunity: It identifies a specific IM-CD4 T cell circuit (driven by CXCL16/CXCR6 and IFN$\gamma$) and the formation of iBALT as the mechanistic basis for why mucosal (IT) delivery is superior.
• Vaccine Optimization: The findings provide a rational framework for developing next-generation TB vaccines. They suggest that mucosal delivery (e.g., intratracheal or intranasal) is superior to systemic (IV/SC) routes for engaging lung-resident IM and establishing spatially organized immune hubs.
• Broad Applicability: The demonstration of heterologous protection against P. aeruginosa suggests that this reprogramming strategy could be effective against other respiratory pathogens, not just TB.

In conclusion, the paper demonstrates that mucosal BCG vaccination uniquely reprograms lung interstitial macrophages through a spatially organized, bidirectional interaction with CD4 T cells, resulting in superior antimicrobial defense against both homologous (Mtb) and heterologous pathogens.